Neutral · 62/100Aug 6, 10:04 PM EDT
TriSalus Reaffirms 2026 Revenue Target of $54M-$57M as CMS G-Code Boosts TriNav Reimbursement in Office-Based Labs
TLSITLSIW
TriSalus Life Sciences (TLSI) reported Q2 2026 revenue exceeding $11.4 million, driven by strong field execution, and reaffirmed its 2026 revenue guidance of $54M-$57M. The expansion of CMS G-code reimbursement for TriNav into office-based labs is expected to…
- ▹CMS G-code expands reimbursement into office-based labs, supporting commercial growth and revenue guidance.
- ▹Single-asset platform with limited pipeline diversification and no major regulatory catalyst.